387867-13-2 | Tandutinib

Packsize	Purity	Availability	Price	Discounted Price
1mg	97%	in stock	$13.00	$9.00
50mg	97%	in stock	$52.00	$36.00
100mg	97%	in stock	$63.00	$44.00
1g	97%	in stock	$428.00	$299.00

Description

• Catalog Number: AD36906
• Chemical Name: Tandutinib
• CAS Number: 387867-13-2
• Molecular Formula: C31H42N6O4
• Molecular Weight: 562.703
• MDL Number: MFCD09954147
• SMILES: COc1cc2c(cc1OCCCN1CCCCC1)ncnc2N1CCN(CC1)C(=O)Nc1ccc(cc1)OC(C)C

Computed Properties

• Complexity: 783
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 41
• Hydrogen Bond Acceptor Count: 8
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 10
• XLogP3: 4.6

Literature

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns.

  Leukemia 20120701

• Midostaurin does not prolong cardiac repolarization defined in a thorough electrocardiogram trial in healthy volunteers.

  Cancer chemotherapy and pharmacology 20120501

• Discovery of the novel potent and selective FLT3 inhibitor 1-{5-[7-(3- morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-p-tolylurea and its anti-acute myeloid leukemia (AML) activities in vitro and in vivo.

  Journal of medicinal chemistry 20120426

• HPLC-DAD protein kinase inhibitor analysis in human serum.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120415

• Preclinical testing of tandutinib in a transgenic medulloblastoma mouse model.

  Journal of pediatric hematology/oncology 20120301

• A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma.

  Investigational new drugs 20120201

• VX-322: a novel dual receptor tyrosine kinase inhibitor for the treatment of acute myelogenous leukemia.

  Journal of medicinal chemistry 20120126

• Antiangiogenic therapy for patients with recurrent and newly diagnosed malignant gliomas.

  Journal of oncology 20120101

• Enhanced brain disposition and effects of Δ9-tetrahydrocannabinol in P-glycoprotein and breast cancer resistance protein knockout mice.

  PloS one 20120101

• Comprehensive analysis of kinase inhibitor selectivity.

  Nature biotechnology 20111030

• Accelerated disease progression in prostate cancer and bone metastases with platelet-derived growth factor receptor inhibition: observations with tandutinib.

  Cancer chemotherapy and pharmacology 20111001

• Multidimensional profiling of CSF1R screening hits and inhibitors: assessing cellular activity, target residence time, and selectivity in a higher throughput way.

  Journal of biomolecular screening 20111001

• Emerging toxic neuropathies and myopathies.

  Neurologic clinics 20110801

• Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.

  European journal of medicinal chemistry 20110601

• Neuromuscular junction toxicity with tandutinib induces a myasthenic-like syndrome.

  Neurology 20110118

• Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity.

  Current medicinal chemistry 20110101

• Survey of activated FLT3 signaling in leukemia.

  PloS one 20110101

• Dose study of the multikinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamics.

  Cancer management and research 20110101

• Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells.

  PloS one 20110101

• New agents targeting angiogenesis in glioblastoma.

  Chemotherapy research and practice 20110101

• P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor.

  Drug metabolism letters 20101201

• The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro.

  Toxicology and applied pharmacology 20101201

• Synthesis and structure-activity relationship of 6-arylureido-3-pyrrol-2-ylmethylideneindolin-2-one derivatives as potent receptor tyrosine kinase inhibitors.

  Bioorganic & medicinal chemistry 20100701

• [FLT3 kinase inhibitors for the treatment of acute leukemia].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20100601

• FLT3 inhibitors for the treatment of acute myeloid leukemia.

  Clinical advances in hematology & oncology : H&O 20100601

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20100101

• Antiangiogenic therapy and mechanisms of tumor resistance in malignant glioma.

  Journal of oncology 20100101

• AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).

  Blood 20091001

• The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin.

  Cell cycle (Georgetown, Tex.) 20090815

• N-(4-Isopropoxyphen-yl)acetamide.

  Acta crystallographica. Section E, Structure reports online 20090501

• ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside.

  Journal of hematology & oncology 20090101

• Patient-derived acute myeloid leukemia (AML) bone marrow cells display distinct intracellular kinase phosphorylation patterns.

  Cancer management and research 20090101

• Gamma-secretase represents a therapeutic target for the treatment of invasive glioma mediated by the p75 neurotrophin receptor.

  PLoS biology 20081101

• Detection of FLT3 oncogene mutations in acute myeloid leukemia using conformation sensitive gel electrophoresis.

  International journal of molecular sciences 20081101

• Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells.

  Blood 20080901

• Tandutinib inhibits FMS receptor signalling, and macrophage and osteoclast formation in vitro.

  Leukemia 20080701

• Can FLT3 inhibitors overcome resistance in AML?

  Best practice & research. Clinical haematology 20080301

• Tandutinib, an oral, small-molecule inhibitor of FLT3 for the treatment of AML and other cancer indications.

  IDrugs : the investigational drugs journal 20080101

• A quantitative analysis of kinase inhibitor selectivity.

  Nature biotechnology 20080101

• FLT3 kinase inhibitors in the management of acute myeloid leukemia.

  Clinical lymphoma & myeloma 20071201

• [Novel molecularly target therapies for leukemia].

  Nihon rinsho. Japanese journal of clinical medicine 20070128

• Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics.

  Blood 20061201

• Improved synthesis of substituted 6,7-dihydroxy-4-quinazolineamines: tandutinib, erlotinib and gefitinib.

  Molecules (Basel, Switzerland) 20060410

• [The present status of, and problems with the development of FLT3 kinase inhibitors].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20060401

• RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518.

  Blood 20050401

• A small molecule-kinase interaction map for clinical kinase inhibitors.

  Nature biotechnology 20050301

• [Current and new therapeutic strategies in acute myeloid leukemia].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050301

• [Possibility of targeting FLT3 kinase for the treatment of leukemia].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20050301

• Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970.

  Blood 20041201

• Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis.

  Blood 20041101

• Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518.

  Blood 20041101

• Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.

  Journal of medicinal chemistry 20020815

• CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).

  Cancer cell 20020601